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Palliative therapy with tamoxifen in inoperable hepatocellular
carcinoma has been often used in the past with controversial
results (Engstrom et al, 1990; Farinati et al, 1990; Elba et al, 1994;
Martin-Cereso et al, 1994): two recent randomized trials of
tamoxifen vs. placebo, however, have definitively demonstrated
that tamoxifen does not exert any beneficial effect (Castells et al,
1995; Gallo and CLIP study group, 1998). 
One possible reason for tamoxifen failure could reside in the
presence, in a substantial percentage of patients with hepatocel-
lular carcinoma (HCC), of variant liver oestrogen receptors (Villa 
et al, 1998): these receptors derive from an exon 5-deleted
oestrogen receptor transcript which gives rise to an oestrogen
receptor altered in the hormone-binding domain (vER), capable,
however, of maintaining a constitutive transcriptional activity
(Fuqua et al, 1991). Tumours characterized by this receptor have
significantly shorter doubling time in comparison with tumours
characterized by wild-type ER (wtER) transcripts, a higher clinical
aggressiveness and are unresponsive to tamoxifen, as this drug
acts blocking the receptor protein by competing for the hormone
binding site and requires an intact receptor to exert its action
(Villa et al, 1995, 1996a, 1996b). A small open trial in 8 patients
suggested that in these patients, a progestin drug like megestrol
(which exerts its action at post-receptorial level) might represent a
better therapeutic option than tamoxifen (Villa et al, 1996a, 1996b). 
We have therefore planned a prospective, randomized, placebo-
controlled study in the attempt to define whether antihormonal
therapy with megestrol may slow down tumour growth and improve
survival in HCC patients with variant ERs. As antihormonal therapy
cannot be considered a radical therapeutical measure, only patients
with inoperable HCC were included in the study. 
MATERIALS AND METHODS 
Selection of patients and treatment protocol 
This prospective, randomized, controlled study was carried out at
the University of Modena between September 1995 and September
1998; enrolment of patients ended in July 1997. Patients were
eligible for the study if they had inoperable HCC, i.e. if clinical
conditions, size (solitary tumour larger than 5 cm) or number (3 or
more nodules) of the neoplastic lesions precluded surgery (Castells
et al, 1993), liver transplant (Mazzaferro et al, 1996) or percuta-
neous ethanol injection (Vilana et al, 1992). 9 patients, when first
seen, had solitary lesions smaller than 5 centimetres: however,
extremely rapid increase of the size of the lesion (8 patients) and
refusal of any type of therapy (n = 1) precluded any attempt of
radical treatment and patients could therefore be enrolled in this
study. Additional criteria for entry was a performance score of at
least 70 on the Karnofsky scale. Demonstrable extrahepatic meta-
stases by total body CT or bone scan and previous or simultaneous
secondary malignant disease excluded patients from the protocol.
The study was approved by the Institutional Ethical Committee of
the University of Modena; patients gave informed written consent
before enrolment in the study. 
Hormonal therapy with megestrol in inoperable
hepatocellular carcinoma characterized by variant
oestrogen receptors 
E Villa, I Ferretti, A Grottola, P Buttafoco, M Grazia Del Buono, F Giannini, M Manno, H Bertani, A Dugani and 
F Manenti 
Department of Internal Medicine, University of Modena, Italy
Summary Variant liver oestrogen receptor transcripts in hepatocellular carcinoma are associated with aggressive clinical course and
unresponsiveness to tamoxifen. To evaluate the impact on survival and on tumour growth of megestrol (progestin drug acting at post-
receptorial level) we enrolled 45 patients with HCC characterized by variant liver oestrogen receptors in a prospective, randomized study with
megestrol vs. placebo. Presence of variant oestrogen receptors was determined by RT/PCR. 24 patients were randomized to no treatment
and 21 to therapy with megestrol 160 mg day –1. Results were analysed by Kaplan-Meier and Cox methods. Survival of hepatocellular
carcinoma characterized by variant oestrogen receptors was extremely poor (median survival 7 months); megestrol significantly improved
survival (18 months) (P  = 0.0090). Tumour growth at one year was significantly slowed down in megestrol-treated patients (P = 0.0212).
Bilirubin levels, presence of portal thrombosis, HBV aetiology and treatment were identified at univariate analysis as factors significantly
associated with survival; at multivariate analysis, only megestrol therapy (P = 0.0003), presence of HBV infection (P = 0.0009) and presence
of portal vein thrombosis (P = 0.0051) were factors independently related with survival. (1) Megestrol slows down the aggressive tumour
growth of patients with hepatocellular carcinoma characterized by variant estrogen receptors and (2) is also able to favourably influence the
course of disease, more than doubling median survival. © 2001 Cancer Research Campaign http://www.bjcancer.com
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doi: 10.1054/ bjoc.2000.1534, available online at http://www.idealibrary.com on  http://www.bjcancer.comPatients underwent ultrasound-assisted liver biopsy as a part of
routine histopathological diagnosis and for evaluation of type of
ER transcript. Written informed consent was obtained from each
patient for the use of part of the biopsy for purpose other than
diagnostic histopathological investigation. ER transcripts were
determined by RT/PCR as already described (Villa et al, 1995). 
Demographic characteristics, aetiology and severity of cirrhosis
(evaluated by Child-Pugh score) were assessed in each patient
(Table 1). 
The inclusion criteria were met by 45 patients, who were
randomly assigned, by sealed envelope method, either to the
control group or to hormonal treatment with megestrol 160 mg
day–1. 
Patients follow up 
In view of the advanced stage of disease in these patients, primary
goal of the study was stabilization of disease and improvement of
survival; treatment was stopped only when relevant side-effects
occurred. All adverse effects were recorded, whether or not they
were considered as drug-related. Patients, both treated and
controls, were seen every 3 months, unless relevant side effects or
complications occurred, in which case they were admitted to
hospital. At each visit, medical history was taken and physical
examination was performed. Laboratory tests (blood count,
alfaetoprotein (AFP), bilirubin, prothrombin time, alkaline
phosphatase, gammaglutam transpeptidase (GGT), serum
albumin) were carried out every 3 months. Magnetic resonance
was performed at month 3, 12 and 24, as already described
(Kaplan and Meier, 1958). 
Virological tests 
HBsAg was determined by Ausria II (Abbott Laboratories,
Chicago, IL). AntiHCV was determined by third generation
ELISA (Ortho Diagnostic Systems, Raritan, NJ). 
Statistical analysis 
Baseline data of patients are reported as mean ± standard deviation
(SD) or median and ranges. Qualitative variables were compared
with chi square test or with Fischer exact test when appropriate
while quantitative variables were compared with Mann-Whitney
U test. All P values were two-tailed and level of significance was
set to 0.05. 
The univariate analysis to identify predictors of survival was
performed by the Kaplan-Meier method (1958) and compared by
the Mantel log-rank test. Data were censored at the time of last
visit. 16 variables were assessed: age, AFP, alkaline phosphatase,
ascites, bilirubin, Child-Pugh score, encephalopathy, aetiology,
gamma-glutamyltranspeptidase (GGT), histology of tumour,
increment of tumour volume at month 3, megestrol treatment,
platelets count, presence of portal vein thrombosis, previous
variceal haemorrhage and sex. For continous variables the cut-off
was set at the median value. All variables were subsequently
analysed by Cox’s regression method (Cox, 1972). 
Time to tumour progression was analysed, according to 
WHO criteria, using the method of Kaplan and Meier (1958).
Progression-free patients were censored at death. User-defined
missing values were treated as missing. 
All calculations were performed with the SPSS/PC plus 2 statis-
tical package (SPSS, Chicago, IL). 
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Table 1 Comparison of the clinical and demographic features at enrolment in the 45 patients studied, divided according to treatment 
Whole group Controls (24) Megestrol (21) Level of 
(%) (%) (%) significance (P) 
Age (mean ± SD)a 62 ± 11 60 ± 11 63 ± 8 0.724 
Males/Females 36/9 22/2 14/7 0.061 
Aetiology 
HBsAg (%) 29 (64.4) 9 (37.5) 6 (28.5) 
AntiHCV (%) 15 (33.3) 15 (62.5) 14 (66.6) 0.487 
Alcohol (%) 1 (2.2) – 1 (4.7) 
Child-Pugh 
A 21 (46.6) 10 (41.6) 11 (52.3) 
B 13 (28.8) 7 (29.1) 6 (28.5) 0.689 
C 10 (24.4) 7 (29.1) 4 (19.0) 
Basal tumour volume (cm3)a 132 ± 251  158 ± 293 104 ± 203 0.334 
Histology 
Well differentiated 23 (51.1) 14 9 
Moderately differentiated 11 (24.4) 5 6 0.604 
Poorly differentiated 6 (13.3) 2 4 
Unknown 5 (11.1) 3 2 
Portal vein thrombosis 5 (11.1) 4 1 0.352 
Tumour stage 
Single nodule <5 cm 9 (20.0) 6 3 
Single nodule >5 cm 15 (33.3) 7 8 0.632 
Multiple nodules or diffuse 21 (46.7) 11 10 
Albumin (g l–1)a 3.2± 0.5 3.1 ± 0.4 3.3 ± 0.4 0.098 
Alkaline phosphatase (IU l–1)a 365 ± 144 334 ± 212 332 ± 144 0.657 
Bilirubin (mg dl–1)a 1.6 ± 0.9  1.7 ± 1.4 1.6 ± 1.9 0.368 
GGT (IU l–1)a 137 ± 130 163 ± 175 157 ± 99 0.045 
Prothrombin time (% activity)a 76 ± 18 77 ± 22 74 ± 15 0.973 
AFP (<100/100–500/>500) 31/3/6 15/1/4 16/2/2  0.738 
a Mann-Whitney test. RESULTS 
Clinical and laboratory data 
135 patients were diagnosed in our unit in the period 1995–1997 as
having HCC; of them, in 14 patients (33.3%) (36 males, 9 females)
had variant ERs transcripts demonstrated in the tumour and were
therefore enrolled in the study. All patients had cirrhosis of the
liver. Clinical and demographic data of the patients at enrolment
are listed in Table 1. Patients in the treated and untreated group
were similar in regard to age, Child-Pugh score, volume of tumour
mass at baseline, histology, presence of portal vein thrombosis,
stage of the tumour and biochemical data; despite higher number
of females in treated group, this difference did not reach signifi-
cance (P = 0.061. Fischer’s exact test). 
Both treated patients and controls were regularly seen in the
outpatient clinic every 3 months; follow-up schedule was exactly
the same and no dropouts occurred. 
24 patients were randomized to no treatment while 21 were
received megestrol 160 mg day–1. No violation of randomization
occurred. 
Survival analysis 
Death occurred in 34 out of 45 patients (75.5%). At the end of
follow-up, the overall median survival was 14 months (95% CI
9.28–18.72 months). The overall actuarial probability of survival
at year 1, 2, 3 and 4 was 52, 19, 15 and 9%, respectively. 
When the patients were divided by treatment, the median
survival in untreated patients was 7 months (95% CI 3.01–10.99
months) versus 18 months (95% CI 13.47–22.53 months) in
megestrol-treated patients (P = 0.0090) (Figure 1). The overall
actuarial probability of survival at year 1, 2, 3 and 4 was 29, 15, 15
and 4% in untreated patients and 83, 25, 15 and 15% in megestrol-
treated patients. 
Of the 16 variables assessed at univariate analysis (Table 2), 4
were found to be significantly related with survival: megestrol
treatment (P = 0.0090); bilirubin levels (P = 0.0451); HBV-related
aetiology (P = 0.0453); presence of portal vein thrombosis (P =
0.0246). Evaluation of treatment effect after adjustment for
patients’ sex evidenced a significant difference in favour of female
patients (males: treated vs. controls: median survival 18 vs. 7
months; 95% CI: 6.36–29.64 and 3.19–10.81 respectively;
females: treated vs. controls median survival 17 vs. 3 months; 95%
CI 15.40–18.60 and 0 respectively) (P = 0.0078). 
All variables from all 45 patients were included in multivariate
analysis. Megestrol treatment (hazard ratio: 0.2098; 95% CI:
0.0894–0.4923; P = 0.0003), HBV-related aetiology (hazard 
ratio: 4.3221; 95% CI: 1.9255–9.7015; P = 0.0009) and presence 
of portal vein thrombosis (hazard ratio: 5.7395; 95% CI: 1.6850–
19.5504;  P = 0.0051) were independent predictive factors of
survival. 
Tumour growth 
Mean tumour mass at baseline was not significantly different
between treated and untreated patients (untreated: 158 ± 293 cm3;
treated 140 ± 203 cm3) (P = 0.334). Analysis to time of first
tumour growth by Kaplan-Meier showed time to progression to be
significantly increased in the treated group (median time 22
months for megestrol-treated patients vs. 9 months for controls,
log rank 5,33, P = 0.0212) (Figure 2). 
Side effects 
Treatment was very well tolerated by the majority of the patients.
Increase in appetite and in weight occurred in 15 (71.4%) and 13
(61.9%) out of 21 treated patients respectively in comparison with
none of the untreated patients. 
One patient (4.1%) in the treated group and one (4.7%) in the
control group developed deep vein thrombosis. One of the female
patients, aged 65, treated with megestrol, experienced moderate
vaginal spotting, which resolved spontaneously, without the need
to stop therapy. 
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Figure 1 Kaplan-Meier estimated probability of survival in treated patients
and controls (P = 0.0090 by Log rank test). 
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Figure 2 Actuarial probability of growth of tumour mass. Increase of tumour
volume was significantly different between control and patients treated with
megestrol (P = 0.0212 by Log rank test). DISCUSSION 
HCC patients whose tumours are characterized by variant ERs
have a definitively more aggressive disease than patients with
wild-type ER: tumours grow very rapidly and survival is signifi-
cantly shorter than in patients in whom liver wild-type receptors
are present (Villa et al, 1997). Indeed, median survival of untreated
patients in the present series was 7 months, despite the fact that
their cirrhotic condition at enrolment was not very advanced, as
indicated by the preserved liver function and by the lack of 
correlation between survival and signs of severity of disease like
Child-Pugh score (P = 8848), presence of ascites (P = 0.7968) or
of encephalopathy (P = 0.4143); paradoxically, subjects with
moderate encephalopathy or moderate ascites had better survival,
perhaps as they had slightly slower course of disease. Megestrol
was able to favourably influence such severe course, significantly
improving survival, which increased from 7 to 18 months, and
slowing down tumour growth. 
Our results are in contrast with those by Chao et al (1991) who
did not find any favourable effect in 32 patients with inoperable
HCC treated with the same dosage of megestrol used in our study.
The authors, however, defined as goal of the study the disappear-
ance or at least the reduction of more than 50% of the tumour
mass, which were not achieved. As the study was not controlled,
the authors did not have the chance to evidence a possible
improvement in survival between treated and control group, which
was instead the most notable result in our series. Indeed, also in
none of our patients was there regression of tumour mass but, in
treated patients tumour progression was significantly slower and
survival longer than in untreated patients. On the other hand, one
should recognize the fact that in both studies, the patients under
investigation were characterized by very advanced disease and in
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Table 2 Evaluation of the prognostic value of variable by Kaplan-Meier analysis (comparison by Log rank test) 
Variable Number of  Number of  Median survival  95% Confidence  Significance (P) 
patients deaths (mo) Interval
Variables with prognostic significance 
Megestrol treatment 
Yes 21 13 18 13.47–22.53 0.0090 
No 24 21 7 3.01–10.99 
Bilirubin ≤ 1.0 mg% 35 25 14 3.69–24.31 0.0451 
> 1.0 mg% 10 9 5 0–15.85 
Aetiology HBV 16 14 7 1.14–12.86 0.0453 
HCV 29 20 17 12.08–21.92 
Portal vein thrombosis 
No 40 30 14 6.71–21.29 0.0246 
Yes 5 4 2 0.93–3.07 
Variables without prognostic significance
Age ≤ 64 years 22 19 13 0.27–25.73  0.9732 
> 64 years 23 15 14 9.42–18.58 
AFP ≤ 21 ng ml–1 20 11 19 9.49–28.51 0.3406
> 21 ng ml–1 20 18 13 6.13–19.87 
Alk. Phosph.  ≤ 280 IU l–1 14 8 16 6.28–25.72 0.1813 
> 280 IU l–1 31 26 10 2.85–17.15 
Ascites Absent 32 24 13 6.6–21.46 0.7968 
Moderate 9 6 14 2.68–25.32 
Severe 4 4 7 0.14–13.86 
Child-Pugh A 22 17 10 3.48–16.52 
B 13 9 14 7.0–20.91 0.8848 
C 10 8 10 0.70–19.30 
Encephalopathy 
Absent 39 29 13 8.70–17.30 0.4143 
Moderate 6 5 19 0–42.52 
GGT < 86 IU l–1 21 16 14 4.08–23.92 0.5236 
> 86 IU l–1 24 18 13 4.28–21.72 
Histology 
Well differentiated 23 19 13 8.60–17.40 
Moderately different. 11 6 24 6.15–41.95  0.4023 
Poorly differentiated 6 5 7 0.00–25.00 
Unknown 5 5 24 4.92–43.08 
% Increment of tumour mass at month 3 
Less than 55% 18 14 14 3.40–24.60 0.6198 
More than 55% 20 15 10 0.97–19.03 
Platelet count 
≤ 100.000 mmc 21 15 17 0.48–33.52 0.8231 
> 100.000 mmc 24 20 14 12.17–15.83 
Previous variceal haemorrhage 40 30 13 6.98–19.02 0.2292 
No 5 4 14 0.00–34.28 
Yes 
Sex Males 36 29 10 4.61–15.39 0.8505 
Females 9 5 16 8.75–23.25 the study by Chao et al also by previous other therapies in more
than 60% of patients, therefore with the worst characteristics in
terms of possible response to therapy. 
Our results suggest also that the sensitivity of HCC patients to
megestrol is probably short-lived: the comparison of the cumula-
tive proportions of survival in treated and untreated patients shows
that there is a net improvement in the first year (83% treated vs.
29% untreated) but afterwards the difference is no longer so
striking and the survival curves of treated and untreated patients
converge. The effect of megestrol is likely not powerful enough to
stop tumour progression but it is able to counteract tumour growth
for a period sufficient to improve significantly the course of the
disease. On the other hand, no other therapeutic regimens, evalu-
ated in a controlled fashion, have so far obtained definite good
results, especially concerning survival, in this type of patients
(Simonetti et al, 1997). 
Both univariate and multivariate analysis indicated, apart from
treatment, HBV-related aetiology as one of the factors negatively
associated with survival. The severe prognosis of patients with
HBV-related disease in comparison with the HCV-positive ones
has been already recognized (Zaman et al, 1985; Villa et al, 1988).
It is possible that in the present series this finding may be due to
the preselection of patients with HCC characterized by variant ER
receptors transcripts: these subjects are in fact significantly more
often HBsAg-positive than HCV-positive (Villa et al, 1998). On
the other hand, the capability of HBV to integrate into host
genome might facilitate the occurrence of alternative splicing
events of ER gene with onset of variant ERs. 
We have not observed a difference in overall survival between
males and females; however hormonal manipulation seemed to
exert a better effect in females than in males despite the fact that
these tumours were all characterized by receptors, like variant
ERs, less sensitive to hormonal manipulation than classical wild-
type ERs (Fuqua, et al, 1991; Villa et al, 1996a). 
In conclusion, our results show that megestrol in patients with
HCC characterized by variant ERs, i.e. in those patients with
rapidly progressive disease, is able to remarkably increase
survival. The effect is not sufficient to cure the disease but the
increased survival together with the very good tolerance of the
drug, the improvement of feeling of well being and the lack of
serious side effects make a trial with this drug more than
warranted. Future efforts should be addressed to identify 
more powerful drugs which could interfere more efficiently 
with the aggressive course of disease in HCC patients with variant
ERs. 
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